Tetra Bio-Pharma Past Earnings Performance
Past criteria checks 0/6
Tetra Bio-Pharma's earnings have been declining at an average annual rate of -42.8%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually.
Key information
-42.8%
Earnings growth rate
-15.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Aug 2022 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Tetra Bio-Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Aug 22 | 0 | -39 | 8 | 5 |
| 31 May 22 | 0 | -41 | 9 | 6 |
| 28 Feb 22 | 0 | -45 | 10 | 7 |
| 30 Nov 21 | 0 | -52 | 12 | 12 |
| 31 Aug 21 | 0 | -29 | 12 | 14 |
| 31 May 21 | 0 | -28 | 10 | 15 |
| 28 Feb 21 | 0 | -25 | 10 | 14 |
| 30 Nov 20 | 0 | -21 | 9 | 12 |
| 31 Aug 20 | 0 | -17 | 9 | 8 |
| 31 May 20 | 0 | -15 | 9 | 6 |
| 29 Feb 20 | 0 | -14 | 8 | 6 |
| 30 Nov 19 | 0 | -13 | 7 | 6 |
| 31 Aug 19 | 0 | -14 | 7 | 8 |
| 31 May 19 | 0 | -10 | 7 | 7 |
| 28 Feb 19 | 0 | -10 | 7 | 7 |
| 30 Nov 18 | 0 | -8 | 6 | 6 |
| 31 Aug 18 | 0 | -5 | 6 | 3 |
| 31 May 18 | 0 | -8 | 6 | 3 |
| 28 Feb 18 | 0 | -7 | 5 | 3 |
| 30 Nov 17 | 0 | -6 | 5 | 2 |
| 31 Aug 17 | 0 | -5 | 3 | 3 |
| 31 May 17 | 0 | -4 | 2 | 2 |
| 28 Feb 17 | 0 | -2 | 1 | 1 |
| 30 Nov 16 | 0 | -1 | 1 | 0 |
| 31 Aug 16 | 0 | -1 | 1 | 0 |
| 31 May 16 | 0 | 0 | 0 | 0 |
| 29 Feb 16 | 0 | 0 | 0 | 0 |
| 30 Nov 15 | 0 | -1 | 0 | 0 |
| 31 Aug 15 | 0 | 0 | 1 | 0 |
Quality Earnings: JAM1 is currently unprofitable.
Growing Profit Margin: JAM1 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: JAM1 is unprofitable, and losses have increased over the past 5 years at a rate of 42.8% per year.
Accelerating Growth: Unable to compare JAM1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: JAM1 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: JAM1's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.